Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Nov-Dec;43(6):1255-1269.
doi: 10.1002/mas.21827. Epub 2022 Dec 10.

Clinical proteomics towards multiomics in cancer

Chad J Creighton  1   2   3
Affiliations
Review

Clinical proteomics towards multiomics in cancer

Chad J Creighton. Mass Spectrom Rev. 2024 Nov-Dec.

Abstract

Recent technological advancements in mass spectrometry (MS)-based proteomics technologies have accelerated its application to study greater and greater numbers of human tumor specimens. Over the last several years, the Clinical Proteomic Tumor Analysis Consortium, the International Cancer Proteogenome Consortium, and others have generated MS-based proteomic profiling data combined with corresponding multiomics data on thousands of human tumors to date. Proteomic data sets in the public domain can be re-examined by other researchers with different questions in mind from what the original studies explored. In this review, we examine the increasing role of proteomics in studying cancer, along with the potential for previous studies and their associated data sets to contribute to improving the diagnosis and treatment of cancer in the clinical setting. We also explore publicly available proteomics and multi-omics data from cancer cell line models to show how such data may aid in identifying therapeutic strategies for cancer subsets.

Keywords: cancer; multiomics; proteogenomics; proteomics.

PubMed Disclaimer

References

REFERENCES

    1. Akbani, R., Ng, P., Werner, H., Shahmoradgoli, M., Zhang, F., Ju, Z., Liu, W., Yang, J., Yoshihara, K., Li, J., et al. (2014). A pan‐cancer proteomic perspective on The Cancer Genome Atlas. Nat Commun 5; 3887.
    1. Aran, D., Sirota, M., and Butte, A. (2015). Systematic pan‐cancer analysis of tumour purity. Nat Commun 6, 8971.
    1. Ashburner, M., Ball, C.A., Blake, J.A., Botstein, D., Butler, H., Cherry, J.M., Davis, A.P., Dolinski, K., Dwight, S.S., and Eppig, J.T. (2000). Gene ontology: tool for the unification of biology. The Gene Ontology Consortium. Nature genetics 25, 25‐29.
    1. Barretina, J., Caponigro, G., Stransky, N., Venkatesan, K., Margolin, A., Kim, S., Wilson, C., Lehár, J., Kryukov, G., Sonkin, D., et al. (2012). The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 483, 603‐607.
    1. Bottoni, P., and Scatena, R. (2015). The role of CA 125 as tumor marker: biochemical and clinical aspects. Adv Exp Med Biol 867, 229‐244.

LinkOut - more resources